PROAMATINE Drug Patent Profile

« Back to Dashboard

Which patents cover Proamatine, and when can generic versions of Proamatine launch?

Proamatine is a drug marketed by Takeda Pharms Usa and is included in one NDA.

The generic ingredient in PROAMATINE is midodrine hydrochloride. There is one drug master file entry for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the midodrine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Proamatine

A generic version of PROAMATINE was approved as midodrine hydrochloride by MYLAN PHARMS INC on September 10^th, 2003.

Summary for PROAMATINE

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	13
Patent Applications:	318
What excipients (inactive ingredients) are in PROAMATINE?	PROAMATINE excipients list
DailyMed Link:	PROAMATINE at DailyMed

Recent Clinical Trials for PROAMATINE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Liver Institute, Egypt	N/A
Northwell Health	Phase 4
National Heart, Lung, and Blood Institute (NHLBI)	Phase 1

See all PROAMATINE clinical trials

US Patents and Regulatory Information for PROAMATINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Usa	PROAMATINE	midodrine hydrochloride	TABLET;ORAL	019815-001	Sep 6, 1996		DISCN	Yes	No
Takeda Pharms Usa	PROAMATINE	midodrine hydrochloride	TABLET;ORAL	019815-002	Sep 6, 1996		DISCN	Yes	No
Takeda Pharms Usa	PROAMATINE	midodrine hydrochloride	TABLET;ORAL	019815-003	Mar 20, 2002		DISCN	Yes	No

ProAmatine (Midodrine) Market Dynamics, Patent Status, and Financial Trajectory

Last updated: October 15, 2026

ProAmatine is the original U.S. brand of midodrine hydrochloride, an oral alpha-1 adrenergic agonist approved for symptomatic orthostatic hypotension. Its commercial position has declined sharply because midodrine is available from multiple generic manufacturers, the product has limited differentiation, and the original brand has no meaningful exclusivity-based pricing power. Current value is concentrated in the generic midodrine market rather than in ProAmatine itself.

What is ProAmatine and how is midodrine used?

ProAmatine contains midodrine hydrochloride and is administered orally. Midodrine and its active metabolite, desglymidodrine, increase vascular tone through alpha-1 adrenergic receptor activity. The FDA-approved indication is treatment of symptomatic orthostatic hypotension, particularly when symptoms materially impair daily functioning.

Product attribute	ProAmatine
Active ingredient	Midodrine hydrochloride
Dosage form	Oral tablet
Original U.S. sponsor	Roberts Pharmaceutical
Subsequent commercial ownership	Shire and related entities
FDA application	NDA 19-815
U.S. approval	1996
Therapeutic class	Alpha-1 adrenergic agonist
Approved indication	Symptomatic orthostatic hypotension
Current competitive status	Generic-dominated
Biosimilar exposure	None
Primary safety issue	Supine hypertension

The FDA label includes a boxed warning concerning supine hypertension. The product is generally taken during waking hours, with the last daily dose given before bedtime to reduce nighttime blood-pressure elevation. Midodrine has also been used off-label in conditions such as autonomic dysfunction and dialysis-associated hypotension, but those uses do not carry the same FDA labeling status as symptomatic orthostatic hypotension.[1]

When did ProAmatine lose exclusivity?

ProAmatine lost practical market exclusivity after generic midodrine products entered the U.S. market. Midodrine is a small-molecule product with a long history of use, and its core patent protection is no longer commercially meaningful.

ProAmatine exclusivity timeline

Period	Event	Commercial effect
1996	FDA approved ProAmatine	Established the branded U.S. product
Late 1990s and 2000s	Brand commercialization and ownership changes	Revenue depended on prescription volume and specialty promotion
2000s	Generic midodrine development and approval activity	Reduced branded pricing power
2010	FDA questioned whether required postmarketing obligations had been completed	Increased regulatory risk around the product’s accelerated-approval history
2011	FDA converted ProAmatine’s approval to traditional approval after postmarketing requirements were addressed	Removed immediate withdrawal risk
2010s onward	Multiple generic suppliers	Shifted the market from branded sales to commodity-style generic supply

The FDA originally approved ProAmatine under the accelerated-approval framework. In 2010, the agency stated that approval could be withdrawn because required postmarketing studies had not been completed. The regulatory issue was later resolved, and the approval was converted to traditional approval after the required evidence was submitted.[2,3]

This regulatory episode did not restore commercial exclusivity. By then, generic competition had already changed the economics of midodrine.

What patents protect ProAmatine and midodrine?

No active, commercially material U.S. patent estate is generally associated with the original ProAmatine product today. Midodrine is an old small molecule, and generic manufacturers have had years to enter the market.

Patent and exclusivity assessment

Protection category	Assessment
Core composition-of-matter patent	Expired or commercially exhausted
Original formulation protection	No current material barrier identified
Method-of-use patents	No known active U.S. patent expected to block ordinary generic use
Pediatric exclusivity	Not a current commercial barrier
Orphan-drug exclusivity	Not applicable to ProAmatine’s original approval
Patent-term extension	No current market effect
Orange Book strategy	No meaningful current branded barrier
Manufacturing protection	Midodrine synthesis is not generally viewed as a high-barrier technology

The original product’s current commercial weakness is consistent with the absence of a live, enforceable exclusivity position that would prevent ANDA-approved competitors from selling midodrine tablets. The FDA Orange Book remains the controlling source for current listed patents and exclusivity entries.[4]

A company considering litigation or licensing around ProAmatine would therefore face a weak basis for asserting legacy composition or conventional tablet claims. A new formulation, delivery system, or combination product could create a separate patent position, but it would not restore protection to ordinary midodrine tablets.

What is the Orange Book status of ProAmatine?

ProAmatine’s Orange Book relevance is limited. The drug’s historical NDA remains important for regulatory lineage, but the product does not have the type of current patent or regulatory exclusivity that would normally support branded pricing.

Generic midodrine products can rely on the reference listed drug pathway through abbreviated new drug applications. The principal legal questions for a generic applicant historically would have involved certification against listed patents and bioequivalence to the reference product. Those barriers are no longer viewed as significant for routine midodrine tablets.

Paragraph IV challenges

Paragraph IV litigation is not a major current driver of the midodrine market. The product’s relevant patents are old, and the market has already experienced generic entry. Any future Paragraph IV filing would likely target a new patent covering a reformulated product, a novel dosage regimen, or a delivery technology rather than the original ProAmatine tablet.

A conventional generic launch would normally create:

1. Price erosion for the brand.
2. Pharmacy substitution.
3. Reduced manufacturer promotion.
4. Declining branded prescription volume.
5. Greater dependence on wholesaler and pharmacy-channel access.

How strong is the ProAmatine patent estate?

The patent estate is weak from a current commercial perspective.

Factors supporting a weak rating

• The active ingredient has been marketed for decades.
• Multiple generic products are available.
• The product is a conventional oral tablet.
• No active composition-of-matter protection is expected to block generic entry.
• There is no biologic manufacturing complexity.
• There is no biosimilar pathway issue.
• The clinical indication is established and relatively narrow.
• Midodrine’s safety limitations constrain premium positioning.

A new entrant could obtain patents around modified-release midodrine, improved tolerability, a transdermal system, or a combination product. Those patents would protect the new product only if the formulation provided a defensible clinical or pharmacokinetic advantage and survived obviousness, enablement, written-description, and infringement challenges.

What is the FDA regulatory status of ProAmatine?

The FDA-approved status of midodrine reflects a conventional small-molecule product with a long regulatory history. The main historical regulatory issue was not initial efficacy failure, but the agency’s concern that postmarketing requirements associated with accelerated approval had not been completed promptly.

The FDA ultimately maintained the product’s approval after the sponsor supplied additional evidence. The approval does not create renewed exclusivity and does not prevent generic competition.

Midodrine remains clinically relevant for selected patients with symptomatic orthostatic hypotension. Its use is limited by supine hypertension, the need for daytime dosing, and the requirement for blood-pressure monitoring. Those limitations reduce its attractiveness as a broad chronic-use product.

What is the market dynamics for ProAmatine and generic midodrine?

The current market is generic-led and price-sensitive. ProAmatine is not positioned as a growth brand. Prescribing decisions are generally influenced by:

• Generic availability.
• Pharmacy substitution.
• Wholesaler supply.
• Tablet strength availability.
• Contract pricing.
• Patient access and reimbursement.
• Physician familiarity with midodrine.
• Clinical need for an inexpensive oral vasoconstrictor.

Midodrine retains demand because treatment alternatives for orthostatic hypotension can be limited. Droxidopa is a key branded comparator, but its price and clinical positioning differ from generic midodrine. Fludrocortisone is another commonly used option, although it has a different mechanism and risk profile.

How does ProAmatine compare with droxidopa?

Attribute	ProAmatine / generic midodrine	Droxidopa
Mechanism	Alpha-1 adrenergic agonist through active metabolite	Norepinephrine precursor
Market position	Generic, low-cost	Branded, higher-cost
FDA indication	Symptomatic orthostatic hypotension	Symptomatic neurogenic orthostatic hypotension
Main safety concern	Supine hypertension	Supine hypertension
Differentiation	Long clinical history and low price	More recent product with neurogenic orthostatic hypotension positioning
Patent value	Legacy protection largely exhausted	Historically stronger branded patent and exclusivity position
Commercial model	Volume and low price	Specialty-brand reimbursement and access management

Midodrine’s principal competitive advantage is cost. Droxidopa’s principal advantage is branded positioning and a more specifically defined indication for neurogenic orthostatic hypotension. The two products are not fully interchangeable from a commercial or clinical standpoint.

What companies are challenging or competing with ProAmatine?

The principal competitors are generic manufacturers rather than branded challengers. Generic midodrine suppliers have included large and specialty pharmaceutical companies operating through ANDAs. Supplier participation can change over time as manufacturers enter, exit, or experience shortages.

The key competitive risks are supply disruption and price compression. Because the product is mature and relatively inexpensive, manufacturers may rationalize production if margins become too low. That creates a market dynamic in which low prices coexist with periodic availability concerns.

Relevant competitive products include:

• Generic midodrine hydrochloride tablets.
• Northera, the brand name for droxidopa.
• Fludrocortisone, generally used off label for orthostatic hypotension.
• Nonpharmacologic interventions such as compression garments and increased fluid or salt intake.

What is the financial trajectory for ProAmatine?

ProAmatine’s standalone financial trajectory is negative relative to its pre-generic period. Public-company reporting has not provided a consistent, current standalone revenue series for the brand. Once generic midodrine gained broad availability, ProAmatine’s economics shifted from a differentiated prescription product to a legacy brand with limited pricing leverage.

Financial trajectory

Phase	Financial profile
Pre-generic period	Brand revenue supported by product differentiation and limited competition
Initial generic entry	Rapid prescription and price pressure
Mature generic period	Brand revenue becomes marginal relative to total midodrine use
Current market	Value resides mainly in generic volume, manufacturing efficiency, and supply reliability

Revenue exposure for a current owner of ProAmatine is therefore likely to be small compared with the commercial value of a protected specialty drug. The more relevant economic opportunity is generic midodrine supply, not brand-price expansion.

Main revenue risks

• Generic substitution.
• Low reimbursement margins.
• Limited ability to raise price.
• Narrow approved indication.
• Safety-related prescribing constraints.
• Lack of active patent protection.
• Potential manufacturing or supply interruptions.
• Competition from droxidopa and off-label alternatives.

A branded relaunch would require a clear reason for physicians and payers to select ProAmatine over generic midodrine. Packaging, adherence support, or marketing alone would likely be insufficient to support a durable premium. A differentiated formulation could change that assessment, but it would require new clinical and patent investment.

What generic launch scenarios exist for ProAmatine?

The base case is continued generic dominance with low brand relevance.

Base case

Generic midodrine remains widely available, and ProAmatine has limited commercial significance. Prices stay low, with periodic variation caused by supplier exits, shortages, or wholesaler contracting.

Upside case for a new owner

A new owner develops an improved formulation, such as extended release or a delivery system that reduces nighttime blood-pressure risk. Regulatory approval and patent protection could support premium pricing if the product demonstrates meaningful clinical value.

Downside case

Generic suppliers reduce production because of weak margins or operational constraints. Temporary shortages could increase short-term prices, but shortages would not create durable brand exclusivity.

What manufacturing and intellectual-property barriers exist?

Manufacturing barriers are modest. Midodrine is a synthetic small molecule supplied in conventional oral tablets. The main technical requirements are control of active pharmaceutical ingredient quality, tablet uniformity, stability, and dissolution performance.

The most meaningful barriers are commercial rather than scientific:

• Reliable API sourcing.
• FDA-compliant manufacturing.
• Consistent supply at low cost.
• Efficient distribution.
• Acceptance by pharmacy benefit managers and wholesalers.

A reformulated product would face higher development costs, clinical requirements, and patent scrutiny. A transdermal or modified-release product could encounter dose-control, absorption, and safety challenges, particularly because excessive alpha-1 activity can cause clinically significant supine hypertension.

What litigation and settlement agreements affect ProAmatine?

No major current patent-litigation program is central to the ProAmatine market. Historical regulatory disputes were more important than ongoing patent litigation. The market’s principal legal structure is the ordinary ANDA framework, not an active branded settlement strategy.

There is no current indication that a settlement agreement materially delays generic midodrine access. Any future litigation would likely concern a reformulated product or a newly patented method of use rather than the legacy ProAmatine tablet.

Key Takeaways

• ProAmatine is the original brand of midodrine hydrochloride.
• The product was FDA approved in 1996 for symptomatic orthostatic hypotension.
• Generic competition has eliminated meaningful brand exclusivity.
• No active, commercially material legacy patent barrier is expected to restrict ordinary generic midodrine.
• ProAmatine’s current standalone revenue is likely marginal and is not publicly reported as a major growth asset.
• Midodrine retains demand because it is inexpensive and clinically familiar.
• Droxidopa is the principal branded comparator, while fludrocortisone is an important off-label alternative.
• The strongest commercial opportunity would involve a differentiated midodrine formulation, not a relaunch of the legacy tablet.
• Manufacturing and supply reliability matter more than patent strength in the mature generic market.
• Biosimilar risk is not applicable because midodrine is a small-molecule drug.

FAQs

Is ProAmatine still available in the United States?

Generic midodrine hydrochloride is the principal U.S. source. Availability of the original ProAmatine brand may vary by distributor and manufacturer status, but the market is overwhelmingly generic.

Is midodrine a controlled substance?

No. Midodrine is not federally scheduled as a controlled substance.

Does midodrine have orphan-drug exclusivity?

No current orphan-drug exclusivity is associated with the original ProAmatine approval.

Can a generic manufacturer launch midodrine without brand litigation?

A generic applicant must satisfy FDA ANDA requirements and address any applicable Orange Book patent certifications. Because the legacy patent position is exhausted, ordinary generic midodrine is not generally viewed as facing a material current patent barrier.

Could a new midodrine formulation obtain patent protection?

Yes. A novel formulation, dosage regimen, delivery system, or combination could receive patent protection if it satisfies statutory patentability requirements. That protection would apply to the new product, not automatically to conventional midodrine tablets.

References

1. U.S. Food and Drug Administration. (2010). ProAmatine (midodrine hydrochloride) prescribing information. FDA.
2. U.S. Food and Drug Administration. (2010, August 16). FDA proposes withdrawal of approval for ProAmatine. FDA.
3. U.S. Food and Drug Administration. (2011). FDA converts approval of ProAmatine to traditional approval. FDA.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
5. U.S. Food and Drug Administration. (2024). Drugs@FDA: Midodrine hydrochloride and ProAmatine regulatory records. FDA.